ALK202

ALK202 · Shanghai Allink Biotherapeutics Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALK202, covering 2025-03-12 to 2025-03-12. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors [Phase 1]

See pricing